DeepMed Research

epoetin alfa

Generic Name: epoetin alfa

Clinical Trials

Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA

Phase 2

Completed

Conditions: Anemia
Chronic Renal Failure
Chronic Kidney Disease

Interventions: Drug: Epoetin Alfa
Drug: peginesatide

First Posted Date: 2008-05-19

Last Posted Date: 2012-06-29

Lead Sponsor: Affymax

Target Recruit Count: 114

Registration Number: NCT00680043

Locations: 🇷🇺
Research Facility, Volzhsk, Russian Federation

A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease

Phase 1

Completed

Conditions: Anemia
Chronic Kidney Disease

First Posted Date: 2008-03-24

Last Posted Date: 2011-05-18

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 40

Registration Number: NCT00641589

Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia

Phase 2

Completed

Conditions: Friedreich's Ataxia

Interventions: Drug: Epoetin alfa

First Posted Date: 2008-03-07

Last Posted Date: 2010-05-27

Lead Sponsor: Federico II University

Target Recruit Count: 10

Registration Number: NCT00631202

Locations: 🇮🇹
Dipartimento di Scienze Neurologiche, Naples, Italy

Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa

Phase 4

Terminated

Conditions: Subarachnoid Hemorrhage

Interventions: Drug: Epoetin alfa
Drug: Saline

First Posted Date: 2008-02-29

Last Posted Date: 2018-07-31

Lead Sponsor: University of South Florida

Target Recruit Count: 3

Registration Number: NCT00626574

Locations: 🇺🇸
Tampa General Hospital, Tampa, Florida, United States

Treatment With Erythropoietin and Cognition During Hypoglycaemia

Not Applicable

Completed

Conditions: Hypoglycemia
Type 1 Diabetes

Interventions: Drug: Isotonic NaCl (Placebo)
Drug: Epoetin alfa

First Posted Date: 2008-02-14

Last Posted Date: 2015-08-24

Lead Sponsor: Hillerod Hospital, Denmark

Target Recruit Count: 11

Registration Number: NCT00615368

Locations: 🇩🇰
Hillerød Hospital, Hillerød, Denmark

A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia

Phase 3

Completed

Conditions: Anemia

Interventions: Drug: Epoetin alfa
Drug: methoxy polyethylene glycol-epoetin beta

First Posted Date: 2008-01-31

Last Posted Date: 2016-05-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 101

Registration Number: NCT00605293

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

Phase 3

Completed

Conditions: Chronic Renal Failure
Chronic Kidney Disease
Anemia

Interventions: Drug: peginesatide
Drug: Epoetin Alfa

First Posted Date: 2008-01-18

Last Posted Date: 2013-02-12

Lead Sponsor: Affymax

Target Recruit Count: 803

Registration Number: NCT00597753

Locations: 🇺🇸
Research Facilities (2), Norfolk, Virginia, United States
🇺🇸
Research Facility, Oshkosh, Wisconsin, United States

Effects of Exercise in Combination With Epoetin Alfa

Not Applicable

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Epoetin Alfa
Behavioral: Exercise
Drug: Total Therapy II
Biological: Autologous Peripheral Blood Stem Cell Transplantation
Biological: Red Blood Cell Transfusion
Drug: Thalidomide
Drug: Heparin, Low-Molecular-Weight
Biological: Platelet Transfusion
Drug: Melphalan

First Posted Date: 2007-12-19

Last Posted Date: 2015-04-06

Lead Sponsor: University of Arkansas

Target Recruit Count: 120

Registration Number: NCT00577096

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Phase 3

Completed

Conditions: Anemia

Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
Drug: Epoetin alfa

First Posted Date: 2007-11-19

Last Posted Date: 2016-04-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 233

Registration Number: NCT00560404

Epoetin Alfa for HIV-Associated Neuropathy Trial

Phase 2

Withdrawn

Conditions: HIV Infections
Neuropathy

Interventions: Drug: epoetin alfa

First Posted Date: 2007-09-12

Last Posted Date: 2011-08-09

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT00528593

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy